Search results for "Cytidine"

showing 10 items of 130 documents

Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing

2014

Gemcitabine is a chemotherapy agent commonly used in the treatment of non-small cell lung cancer (NSCLC) that has been demonstrated to induce apoptosis in NSCLC cells by increasing functionally active Fas expression. The aim of this study was to evaluate the Fas/Fas ligand (FasL) system involvement in gemcitabine-induced lung cancer cell killing. NSCLC H292 cells were cultured in the presence or absence of gemcitabine. FasL mRNA and protein were evaluated by real-time PCR, and by Western blot and flow cytometry, respectively. Apoptosis of FasL-expressing cells was evaluated by flow cytometry, and caspase-8 and caspase-3 activation by Western blot and a colorimetric assay. Cytotoxicity of ly…

Cytotoxicity ImmunologicAntimetabolites AntineoplasticFas Ligand ProteinLung NeoplasmsImmunologychemical and pharmacologic phenomenaApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioDeoxycytidineFas ligandFlow cytometryCarcinoma Non-Small-Cell LungCell Line TumormedicineImmunology and AllergyCytotoxic T cellHumansfas ReceptorLung cancerAutocrine signallingKiller Cells Lymphokine-ActivatedCaspase 8Lymphokine-activated killer cellmedicine.diagnostic_testChemistryCaspase 3Original Articlesmedicine.diseaseMolecular biologyGemcitabineGemcitabineApoptosisapoptosis cytotoxic lymphocytes non-small cell lung cancermedicine.drug
researchProduct

Excision of Uracil from Transcribed DNA Negatively Affects Gene Expression

2014

Uracil is an unavoidable aberrant base in DNA, the repair of which takes place by a highly efficient base excision repair mechanism. The removal of uracil from the genome requires a succession of intermediate products, including an abasic site and a single strand break, before the original DNA structure can be reconstituted. These repair intermediates are harmful for DNA replication and also interfere with transcription under cell-free conditions. However, their relevance for cellular transcription has not been proved. Here we investigated the influence of uracil incorporated into a reporter vector on gene expression in human cells. The expression constructs contained a single uracil opposi…

DNA RepairTranscription GeneticGreen Fluorescent ProteinsGene ExpressionDNA and ChromosomesBiologyBiochemistryCell LineDNA Glycosylaseschemistry.chemical_compoundGenes ReporterActivation-induced (cytidine) deaminaseHumansheterocyclic compoundsProtein–DNA interactionAP siteUracilUracil-DNA GlycosidaseMolecular BiologyUracilDNACell BiologyBase excision repairMolecular biologyThymine DNA GlycosylasechemistryDNA glycosylaseGene Knockdown TechniquesUracil-DNA glycosylasebiology.proteinHeLa CellsNucleotide excision repairJournal of Biological Chemistry
researchProduct

The high rate of endoreduplication in the repair deficient CHO mutant EM9 parallels a reduced level of methylated deoxycytidine in DNA

2008

It has been recently proposed that hypomethylation of DNA induced by 5-azacytidine (5-azaC) leads to reduced chromatid decatenation that ends up in endoreduplication, most likely due to a failure in topo II function [S. Mateos, I. Domínguez, N. Pastor, G. Cantero, F. Cortés, The DNA demethylating 5-azaC induces endoreduplication in cultured Chinese hamster cells, Mutat. Res. 578 (2005) 33-42]. The Chinese hamster mutant cell line EM9 has a high spontaneous frequency of endoreduplication as compared to its parental line AA8. In order to see if this is related to the degree of DNA methylation, we have investigated the basal levels of both endpoints in AA8 and EM9, as well as the effect of ext…

DNA ReplicationDNA RepairHealth Toxicology and MutagenesisMutantCHO CellsChromosome segregationamedicine.disease_causeDeoxycytidineChromosomesChinese hamsterHypomethylation of DNAchemistry.chemical_compoundCricetulusCricetinaeGeneticsmedicineAnimalsEndoreduplicationMolecular BiologyMutationbiologyChinese hamster ovary cellEndoreduplicationDNA Methylationbiology.organism_classificationTopoisomerase IIMolecular biologychemistryMutationDNA methylationAzacitidineChromatidDNAMutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
researchProduct

Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy

2016

The biopharmaceutical properties of supramolecular vesicular aggregates (SVAs) were characterized with regard to their physicochemical features and compared with cationic liposomes (CLs). Neutral and cationic SVAs were synthesized using two different copolymers of poly(aspartyl hydrazide) by thin-layer evaporation and extrusion techniques. Both copolymers were self-assembled in pre-formulated liposomes and formed neutral and cationic SVAs. Gemcitabine hydrochloride (GEM) was used as an anticancer drug and loaded by a pH gradient remote loading procedure, which significantly increased drug loading inside the SVAs. The resulting average size of the SVAs was 100 nm. The anticancer activity of …

DrugBiodistributionMacromolecular Substancesmedia_common.quotation_subjectSupramolecular chemistryAntineoplastic Agents02 engineering and technology010402 general chemistryHydrazideDeoxycytidine01 natural sciencesBiochemistryGemcitabine Hydrochloridesupramolecular chemistryStructure-Activity Relationshipchemistry.chemical_compoundDrug Delivery SystemsCationsDrug DiscoveryTumor Cells CulturedAnimalsHumansTissue DistributionCationic liposomeRats WistarGeneral Pharmacology Toxicology and Pharmaceuticsvesicular aggregatesCell Proliferationmedia_commonPharmacologyLiposomeDose-Response Relationship DrugMolecular StructurenanoparticleOrganic ChemistryCationic polymerization021001 nanoscience & nanotechnologyGemcitabineRats0104 chemical scienceschemistryBiochemistryantitumor agentliposomeMolecular MedicineDrug Screening Assays Antitumor0210 nano-technologyChemMedChem
researchProduct

The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma

2021

Background and aims Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and a highly lethal malignancy. Chemotherapeutic options are limited, but a considerable subset of patients harbors genetic lesions for which targeted agents exist. Fibroblast growth factor receptor 2 (FGFR2) fusions belong to the most frequent and therapeutically relevant alterations in ICC, and the first FGFR inhibitor was recently approved for the treatment of patients with progressed, fusion-positive ICC. Response rates of up to 35% indicate that FGFR-targeted therapies are beneficial in many but not all patients. Thus far, no established biomarkers exist that predict resistance or r…

Fetal Proteins0301 basic medicineAntimetabolites AntineoplasticCombination therapymedicine.medical_treatmentFGFR InhibitionVesicular Transport ProteinsCyclic AMP Response Element-Binding Protein Amedicine.disease_causeDeoxycytidineMalignant transformationTargeted therapyCholangiocarcinomaProto-Oncogene Proteins p21(ras)Mice03 medical and health sciencesLiver Neoplasms Experimental0302 clinical medicineAntigens NeoplasmmedicineAnimalsReceptor Fibroblast Growth Factor Type 2Protein Kinase InhibitorsCell ProliferationHepatologyOncogenebusiness.industryFibroblast growth factor receptor 2AdenosylhomocysteinasePhenylurea CompoundsGemcitabineBile Ducts IntrahepaticCell Transformation NeoplasticPyrimidines030104 developmental biologyBile Duct NeoplasmsFibroblast growth factor receptorMutationCancer research030211 gastroenterology & hepatologyKRASGene FusionbusinessCo-Repressor ProteinsMicrotubule-Associated ProteinsHepatology
researchProduct

Role and importance of polymorphisms with respect to DNA methylation for the expression of CYP2E1 enzyme

2014

Different individuals possess slightly different genetic information and show genetically-determined differences in several enzyme activities due to genetic variability. Following an integrated approach, we studied the polymorphisms and methylation of sites contained in the 5' flanking region of the metabolizing enzyme CYP2E1 in correlation to its expression in both tumor and non-neoplastic liver cell lines, since to date little is known about the influence of these (epi)genetic elements in basal conditions and under induction by the specific inductor and a demethylating agent. In treated cells, reduced DNA methylation, assessed both at genomic and gene level, was not consistently associate…

Genotype5' Flanking RegionCell Survival5' flanking regionMinisatellite RepeatsBiologyGene Expression Regulation EnzymologicGenotypeGeneticsCYP2E1 gene polymorphismTumor Cells CulturedHumansGeneHepatocellular carcinoma cell lines; CYP2E1 gene polymorphisms; DNA methylation; 5-Azacytidine; Ethanol;GeneticsPolymorphism GeneticEthanolLiver cellHaplotype5-AzacytidineCytochrome P-450 CYP2E1General MedicineMethylationHep G2 CellsHepatocellular carcinoma cell lineDNA MethylationMolecular biologySettore BIO/18 - GeneticaDNA methylationAzacitidineRestriction fragment length polymorphismPolymorphism Restriction Fragment Length
researchProduct

Synthesis of diorganotin(IV) complexes with nucleosides and their Characterization by Mössbauer and infrared spectroscopy

1984

Abstract A number of new complexes of R 2 Sn IV with adenosine, guanosine, inosine, cytidine and uridine were synthesized by reaction of ribonucleosides with diorganotin oxide in hot methanol. The complexes were characterized by infrared and 119 Sn Mossbauer spectroscopy as O(2′), O(3′) (diorganostannylene) nucleosides; the occurence of dimers with three-co-ordinate oxygen atoms is inferred on the basis of spectroscopic data.

InfraredInorganic chemistryGuanosineInfrared spectroscopyCytidineUridineInorganic Chemistrychemistry.chemical_compoundCrystallographychemistryMössbauer spectroscopyMaterials ChemistrymedicinePhysical and Theoretical ChemistryInosineNucleosidemedicine.drugInorganica Chimica Acta
researchProduct

Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells

2020

A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized and screened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Two out of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the half maximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 μM, and 0.29–12.2 μM, respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferative activity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized (SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), elici…

Inhibition of migrationAntimetabolites AntineoplasticEpithelial-Mesenchymal Transition3Modulation of EMTPTK2VimentinAntineoplastic AgentsApoptosisThiophenesAntiproliferative activity1-b][1DeoxycytidinePancreatic ductal adenocarcinomaThiadiazolesSDG 3 - Good Health and Well-beingCell MovementPancreatic cancerDrug DiscoveryThiadiazolesmedicineTumor Cells CulturedImidazo[21-b][134]thiadiazole derivativesHumansPTK2/FAKIC50Cell ProliferationImidazo[2Pharmacologybiology4]thiadiazole derivativesChemistryOrganic ChemistryDrug SynergismGeneral Medicinemedicine.diseaseGemcitabinePancreatic NeoplasmsCell cultureDrug Resistance NeoplasmImidazo[21-b][134]thiadiazole derivatives Pancreatic ductal adenocarcinoma Antiproliferative activity Inhibition of migration Spheroids shrinkage Modulation of EMT PTK2/FAKbiology.proteinCancer research/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPhosphorylationSpheroids shrinkageTyrosine kinaseCarcinoma Pancreatic DuctalEuropean Journal of Medicinal Chemistry
researchProduct

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract can…

2019

Background To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) have demonstrated disappointing results, highlighting the complexity of CCA. Recently, drugs aiming at the inhibition of HER-receptors have shown first therapeutic benefit in patients with late stage disease. The aim of this phase I study was to test the dose level toxicities (DLTs), safety and efficacy of afatinib, a highly specific panErbB family receptor TKI, in chemotherapy naive patients with ad…

Male0301 basic medicineOncologyCancer ResearchAfatinibDeoxycytidineTranslational Research BiomedicalCholangiocarcinoma0302 clinical medicineSurgical oncologyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasismedia_commonAged 80 and overpanHER inhibitionMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryErbB ReceptorsBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisBiomarker (medicine)FemaleTyrosine kinaseSignal TransductionResearch Articlemedicine.drugAdultDrugmedicine.medical_specialtyBIBW 2992media_common.quotation_subjectEGFRAfatiniblcsh:RC254-28203 medical and health sciencesInternal medicineGeneticsmedicineHumansProgression-free survivalAgedNeoplasm StagingCisplatinbusiness.industryGemcitabineGemcitabine030104 developmental biologyCisplatinbusinessBiomarkersBMC Cancer
researchProduct

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions

2004

Abstract Objectives To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystosco…

MaleAntimetabolites Antineoplasticmedicine.medical_specialtyUrologyUrinary systemUrologySalvage therapyDeoxycytidineDisease-Free SurvivalSettore MED/24 - UrologiamedicineCarcinomaHumansProdrugsAgedSalvage TherapyCarcinoma Transitional CellUrinary bladderDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryRemission InductionCystoscopyMiddle Agedmedicine.diseaseGemcitabineGemcitabineGemcitabineSurgeryAdministration IntravesicalTreatment Outcomemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTolerabilityFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drug
researchProduct